News
-
HRA Pharma’s Partner, PregLem, The Wholly Owned Subsidiary Of Gedeon Richter Plc, Receives Positive CHMP Opinion For Uterine Fibroids Treatment
12/20/2011
HRA Pharma announces that the Committee for Medicinal Products for Human Use (CHMP), part of the European Medicines Agency (EMA), has issued a positive opinion recommending a marketing authorization for Esmya (ulipristal acetate) for pre operative treatment (3months) of moderate to severe symptoms in patients with uterine fibroids.
-
MIT Research: Proteins Linked To Longevity May Be Involved In Mood Control
12/12/2011
Over the past decade, MIT biologist Leonard Guarente and others have shown that very-low-calorie diets provoke a comprehensive physiological response that promotes survival, all orchestrated by a set of proteins called sirtuins. By Anne Trafton, MIT
-
Roche NimbleGen And BGI Develop Advanced MHC Region Capture Technology For Human Disease And Biomedical Research
11/30/2011
Roche NimbleGen, Inc. and BGI, the world’s largest genomic organization, announced that they have developed a Major Histocompatibility Complex (MHC) region capture technology based on NimbleGen SeqCap EZ Choice Library, a revolutionary process for the enrichment of the MHC region.
-
Virginia G. Piper Cancer Center & TGen Form Drug Development Collaboration With Cedars-Sinai
11/10/2011
The Virginia G. Piper Cancer Center at Scottsdale Healthcare is expanding its efforts to accelerate advances in cancer care with the addition of Cedars-Sinai's Samuel Oschin Comprehensive Cancer Institute in Los Angeles as a collaborator in clinical trials to develop personalized therapies that could lead to more effective cancer treatments.
-
Novartis Phase III Study Shows ACZ885 Helped Substantially Reduce Steroid Use In 45% Of Patients With Serious Form Of Childhood Arthritis
11/8/2011
Novartis announced recently new pivotal Phase III data showing 45% of children with active systemic juvenile idiopathic arthritis (SJIA) were able to substantially reduce their use of oral corticosteroids (often described as steroids) within 28 weeks of commencing treatment with ACZ885 (canakinumab) (p<0.0001).
-
Advance Toward A Breath Test To Diagnose Multiple Sclerosis
10/27/2011
Scientists are reporting the development and successful tests in humans of a sensor array that can diagnose multiple sclerosis (MS) from exhaled breath, an advance that they describe as a landmark in the long search for a fast, inexpensive and non-invasive test for MS — the most common neurological disease in young adults.
-
Merck Announces Presentation Of Phase III Investigational Studies Evaluating DULERA® (Mometasone Furoate And Formoterol Fumarate Dihydrate) Inhalation Aerosol in Chronic Obstructive Pulmonary Disease (COPD)
10/27/2011
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced results from two 26-week investigational Phase III clinical studies evaluating the efficacy and safety of two dose strengths of DULERA® (mometasone furoate and formoterol fumarate dihydrate) in adults 40 years and older with moderate to very severe chronic obstructive pulmonary disease (COPD).
-
Biogen Idec And Elan Receive Notification Of PDUFA Date Extension
10/20/2011
Today Biogen Idec and Elan Corporation, plc announced that the U.S. Food and Drug Administration (FDA) has extended the initial PDUFA date for its review of the supplemental Biologics License Application (sBLA) for TYSABRI® (natalizumab).
-
Phase II Study Showed Ocrelizumab Maintained Significant Reduction In Disease Activity For Multiple Sclerosis Patients For Almost Two Years
10/19/2011
Genentech, a member of the Roche Group, recently announced 96-week results1 from a Phase II study of ocrelizumab in patients with relapsing-remitting multiple sclerosis (RRMS), the most common clinical form2 of the disease.
-
Novartis Drug Gilenya (Fingolimod) Has More Than 20,000 Patient-Years Of Exposure And Shows Up To 71% Reduction In Annualized Relapse Rates In MS Patients With Highly Active Disease
10/18/2011
Novartis will showcase data from 13 abstracts on fingolimod (Gilenya), at the 5th Joint Triennial Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) and Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) taking place from 19-22 October in Amsterdam.
This website uses cookies to ensure you get the best experience on our website. Learn more